Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIANTI
2024-513486-39-00Phase 3Authorised
- Sponsor
- Radboud University Medical Center
- Start
- Dec 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in aortic stenosis (AS), aortic valve calcification (CAVD), aortic valve disease (AVD) and 1 more comparing Colchicine with Placebo (2 arms). Primary endpoint: Change in aortic valve calcium score. Planned start Dec 2024; status: authorised.
02
Drugs
colchicine
03
Conditions
aortic stenosis (AS)aortic valve calcification (CAVD)aortic valve disease (AVD)cardiac morbidity
Beyond the preview
Go deeper on 2024-513486-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513486-39-00.